Claims for Patent: 8,623,819

Summary for Patent: 8,623,819

Title:	Therapy for complications of diabetes
Abstract:	A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
Inventor(s):	Robert L. Roden, Richard J. Gorczynski, Michael J. Gerber
Assignee:	AbbVie Deutschland GmbH and Co KG
Application Number:	US13/766,266
Patent Claims:	1. A method for delaying progression of diabetic nephropathy in a human subject in need of treatment for diabetic nephropathy comprising: administering to the subject atrasentan or a salt thereof, and a dose of at least one of an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and wherein the method delays the progression of diabetic nephropathy. 2. The method of claim 1, wherein the method further comprises reducing incidence or severity of adverse cardiac events. 3. The method of claim 1, comprising administering the dose of the angiotensin converting enzyme inhibitor or angiotensin II receptor blocker at an adequate dose labeled for a hypertension indication. 4. The method of claim 1, comprising administering the dose of the angiotensin converting enzyme inhibitor or angiotensin II receptor blocker at a highest dose labeled for a hypertension indication. 5. The method of claim 1, comprising administering the dose of the angiotensin converting enzyme inhibitor or angiotensin II receptor blocker at a highest usual dose prescribed according to Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), British Hypertensive Society (BHD-IV), European Society of Hypertension/European Society of Cardiology (ESH/ESC) or World Health Organization/International Society of Hypertension (WHO/ISH) guidelines. 6. The method of claim 1, comprising administering the dose of the angiotensin converting enzyme inhibitor or angiotensin II receptor blocker at a highest tolerated dose in the human subject. 7. The method of claim 1, wherein the angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, eosinopril, fosinopril, imidapril, lisinopril, moexipril, moveltipril, omapatrilat, perindopril, quinapril, ramipril, sampatrilat, spirapril, temocapril, trandolapril, and combinations thereof. 8. The method of claim 1, wherein the angiotensin II receptor blocker is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan, valsartan and combinations thereof. 9. The method of claim 1, wherein the method further comprises administering a thiazide diuretic selected from the group consisting of althiazide, bendroflumethiazide, benzthiazide, benzylhydrochlorothiazide, buthiazide, chlorothiazide, chlorthalidone, cyclopenthiazide, cyclothiazide, ethiazide, fenquizone, hydrochlorothiazide, hydroflumethiazide, indapamide, methyclothiazide, metolazone, paraflutizide, polythiazide, quinethazone, teclothiazide, trichlormethiazide, and combinations thereof. 10. The method of claim 1, wherein the method further comprises administering a loop diuretic selected from the group consisting of bumetanide, furosemide, torsemide and combinations thereof. 11. The method of claim 1, wherein the diabetic nephropathy is overt diabetic nephropathy. 12. The method of claim 1, comprising administering the atrasentan or a salt thereof for a period of at least about 3 months. 13. The method of claim 1, comprising administering the atrasentan or a salt thereof for as long as a therapeutic benefit is provided thereby and any adverse side effect thereof remain commensurate with the therapeutic benefit. 14. The method of claim 1, comprising administering the atrasentan or a salt thereof concomitantly with the angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker. 15. A method for extending the time to end-stage renal disease or chronic kidney failure in a human subject in need of treatment comprising: administering to the subject atrasentan or a salt thereof, and a dose of at least one of an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and wherein the method extends the time to end-stage renal disease or chronic kidney failure.